MCM
PHAT icon

Moore Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Moore Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-600,000
Closed -$9.95M – 788
2025
Q4 		$9.95M Hold
600,000
– – 0.2% 162
2025
Q3 		$7.06M Hold
600,000
– – 0.14% 193
2025
Q2 		$5.75M Buy
+600,000
New +$3.32M 0.11% 201
2024
Q4 		– Sell
-130,000
Closed -$2.35M – 620
2024
Q3 		$2.35M Buy
130,000
+10,000
+8% +$140K 0.07% 290
2024
Q2 		$1.24M Hold
120,000
– – 0.03% 295
2024
Q1 		$1.27M Buy
120,000
+20,000
+20% +$170K 0.03% 289
2023
Q4 		$913K Buy
100,000
+20,000
+25% +$172K 0.02% 283
2023
Q3 		$830K Buy
80,000
+20,000
+33% +$274K 0.02% 309
2023
Q2 		$859K Buy
+60,000
New +$692K 0.02% 318

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.08B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return